Baidu
map

Crit Care:脓毒性休克合并急性肾损伤的成年烧伤患者高容量血液滤过疗效分析!

2017-12-04 xing.T MedSci原创

由此可见,HVHF能有效逆转脓毒性休克合并AKI的烧伤患者休克和改善器官功能,并且较为安全。逆转这些患者的休克是否能改善生存率尚待进一步研究确定。

脓毒症和脓毒性休克经常发生于严重烧伤的患者。急性肾损伤(AKI)也较为常见,并且常常是败血症的结局。发生了需要接受肾脏替代治疗AKI的烧伤患者的死亡率高得令人无法接受,当其合并脓毒性休克时推测死亡率会更高。近日,危重病医学领域权威杂志Critical Care上发表了一篇研究文章,研究人员假设高容量血液滤过(HVHF)作为血液净化技术对这类人群有益。

研究人员进行了一项多中心、前瞻性、随机对照临床试验,以评估HVHF对感染性休克合并AKI的烧伤患者血流动力学的影响。受试者随机分配到按照70ml/kg/h剂量HVHF治疗48小时,而对照受试者以标准方式进行处理。

在4年期间内,28名受试者被随机分配,分别有14名进入对照组和HVHF组。该研究由于招募受试者缓慢而终止。与HVHF组基线相比,该研究的主要终点(血管升压药依赖指数)在48小时明显下降(P=0.007),而对照组没有显著差异。当与治疗开始时比较,HVHF组在14天时的多器官功能障碍综合征评分显著下降(P=0.02)。在48小时的干预期间炎症标志物无显著变化。生存率无显著差异,两组间患者之间不良事件也无差异。

由此可见,HVHF能有效逆转脓毒性休克合并AKI的烧伤患者休克和改善器官功能,并且较为安全。逆转这些患者的休克是否能改善生存率尚待进一步研究确定。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1674612, encodeId=e4c316e4612d1, content=<a href='/topic/show?id=255c6e146aa' target=_blank style='color:#2F92EE;'>#烧伤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67146, encryptionId=255c6e146aa, topicName=烧伤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b15f27034396, createdName=俅侠, createdTime=Mon Jul 23 15:26:00 CST 2018, time=2018-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1647183, encodeId=9092164e18381, content=<a href='/topic/show?id=e9bae04003f' target=_blank style='color:#2F92EE;'>#疗效分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70400, encryptionId=e9bae04003f, topicName=疗效分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219323401160, createdName=rebeccajiejie, createdTime=Sun May 27 10:26:00 CST 2018, time=2018-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687090, encodeId=45cb168e0901b, content=<a href='/topic/show?id=b038851865c' target=_blank style='color:#2F92EE;'>#脓毒性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85186, encryptionId=b038851865c, topicName=脓毒性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd9828318255, createdName=1249857fm41暂无昵称, createdTime=Mon Jun 18 20:26:00 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290274, encodeId=6b2912902e44f, content=<a href='/topic/show?id=7d058518e56' target=_blank style='color:#2F92EE;'>#脓毒性休克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85187, encryptionId=7d058518e56, topicName=脓毒性休克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Wed Dec 06 01:26:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397405, encodeId=5b19139e405a6, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Wed Dec 06 01:26:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266939, encodeId=62a8266939aa, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Dec 05 08:45:14 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266722, encodeId=9565266e22e7, content=学习了.好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Dec 04 11:33:35 CST 2017, time=2017-12-04, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1674612, encodeId=e4c316e4612d1, content=<a href='/topic/show?id=255c6e146aa' target=_blank style='color:#2F92EE;'>#烧伤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67146, encryptionId=255c6e146aa, topicName=烧伤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b15f27034396, createdName=俅侠, createdTime=Mon Jul 23 15:26:00 CST 2018, time=2018-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1647183, encodeId=9092164e18381, content=<a href='/topic/show?id=e9bae04003f' target=_blank style='color:#2F92EE;'>#疗效分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70400, encryptionId=e9bae04003f, topicName=疗效分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219323401160, createdName=rebeccajiejie, createdTime=Sun May 27 10:26:00 CST 2018, time=2018-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687090, encodeId=45cb168e0901b, content=<a href='/topic/show?id=b038851865c' target=_blank style='color:#2F92EE;'>#脓毒性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85186, encryptionId=b038851865c, topicName=脓毒性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd9828318255, createdName=1249857fm41暂无昵称, createdTime=Mon Jun 18 20:26:00 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290274, encodeId=6b2912902e44f, content=<a href='/topic/show?id=7d058518e56' target=_blank style='color:#2F92EE;'>#脓毒性休克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85187, encryptionId=7d058518e56, topicName=脓毒性休克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Wed Dec 06 01:26:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397405, encodeId=5b19139e405a6, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Wed Dec 06 01:26:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266939, encodeId=62a8266939aa, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Dec 05 08:45:14 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266722, encodeId=9565266e22e7, content=学习了.好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Dec 04 11:33:35 CST 2017, time=2017-12-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1674612, encodeId=e4c316e4612d1, content=<a href='/topic/show?id=255c6e146aa' target=_blank style='color:#2F92EE;'>#烧伤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67146, encryptionId=255c6e146aa, topicName=烧伤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b15f27034396, createdName=俅侠, createdTime=Mon Jul 23 15:26:00 CST 2018, time=2018-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1647183, encodeId=9092164e18381, content=<a href='/topic/show?id=e9bae04003f' target=_blank style='color:#2F92EE;'>#疗效分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70400, encryptionId=e9bae04003f, topicName=疗效分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219323401160, createdName=rebeccajiejie, createdTime=Sun May 27 10:26:00 CST 2018, time=2018-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687090, encodeId=45cb168e0901b, content=<a href='/topic/show?id=b038851865c' target=_blank style='color:#2F92EE;'>#脓毒性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85186, encryptionId=b038851865c, topicName=脓毒性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd9828318255, createdName=1249857fm41暂无昵称, createdTime=Mon Jun 18 20:26:00 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290274, encodeId=6b2912902e44f, content=<a href='/topic/show?id=7d058518e56' target=_blank style='color:#2F92EE;'>#脓毒性休克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85187, encryptionId=7d058518e56, topicName=脓毒性休克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Wed Dec 06 01:26:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397405, encodeId=5b19139e405a6, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Wed Dec 06 01:26:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266939, encodeId=62a8266939aa, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Dec 05 08:45:14 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266722, encodeId=9565266e22e7, content=学习了.好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Dec 04 11:33:35 CST 2017, time=2017-12-04, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1674612, encodeId=e4c316e4612d1, content=<a href='/topic/show?id=255c6e146aa' target=_blank style='color:#2F92EE;'>#烧伤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67146, encryptionId=255c6e146aa, topicName=烧伤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b15f27034396, createdName=俅侠, createdTime=Mon Jul 23 15:26:00 CST 2018, time=2018-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1647183, encodeId=9092164e18381, content=<a href='/topic/show?id=e9bae04003f' target=_blank style='color:#2F92EE;'>#疗效分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70400, encryptionId=e9bae04003f, topicName=疗效分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219323401160, createdName=rebeccajiejie, createdTime=Sun May 27 10:26:00 CST 2018, time=2018-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687090, encodeId=45cb168e0901b, content=<a href='/topic/show?id=b038851865c' target=_blank style='color:#2F92EE;'>#脓毒性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85186, encryptionId=b038851865c, topicName=脓毒性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd9828318255, createdName=1249857fm41暂无昵称, createdTime=Mon Jun 18 20:26:00 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290274, encodeId=6b2912902e44f, content=<a href='/topic/show?id=7d058518e56' target=_blank style='color:#2F92EE;'>#脓毒性休克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85187, encryptionId=7d058518e56, topicName=脓毒性休克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Wed Dec 06 01:26:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397405, encodeId=5b19139e405a6, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Wed Dec 06 01:26:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266939, encodeId=62a8266939aa, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Dec 05 08:45:14 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266722, encodeId=9565266e22e7, content=学习了.好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Dec 04 11:33:35 CST 2017, time=2017-12-04, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1674612, encodeId=e4c316e4612d1, content=<a href='/topic/show?id=255c6e146aa' target=_blank style='color:#2F92EE;'>#烧伤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67146, encryptionId=255c6e146aa, topicName=烧伤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b15f27034396, createdName=俅侠, createdTime=Mon Jul 23 15:26:00 CST 2018, time=2018-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1647183, encodeId=9092164e18381, content=<a href='/topic/show?id=e9bae04003f' target=_blank style='color:#2F92EE;'>#疗效分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70400, encryptionId=e9bae04003f, topicName=疗效分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219323401160, createdName=rebeccajiejie, createdTime=Sun May 27 10:26:00 CST 2018, time=2018-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687090, encodeId=45cb168e0901b, content=<a href='/topic/show?id=b038851865c' target=_blank style='color:#2F92EE;'>#脓毒性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85186, encryptionId=b038851865c, topicName=脓毒性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd9828318255, createdName=1249857fm41暂无昵称, createdTime=Mon Jun 18 20:26:00 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290274, encodeId=6b2912902e44f, content=<a href='/topic/show?id=7d058518e56' target=_blank style='color:#2F92EE;'>#脓毒性休克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85187, encryptionId=7d058518e56, topicName=脓毒性休克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Wed Dec 06 01:26:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397405, encodeId=5b19139e405a6, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Wed Dec 06 01:26:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266939, encodeId=62a8266939aa, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Dec 05 08:45:14 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266722, encodeId=9565266e22e7, content=学习了.好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Dec 04 11:33:35 CST 2017, time=2017-12-04, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1674612, encodeId=e4c316e4612d1, content=<a href='/topic/show?id=255c6e146aa' target=_blank style='color:#2F92EE;'>#烧伤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67146, encryptionId=255c6e146aa, topicName=烧伤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b15f27034396, createdName=俅侠, createdTime=Mon Jul 23 15:26:00 CST 2018, time=2018-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1647183, encodeId=9092164e18381, content=<a href='/topic/show?id=e9bae04003f' target=_blank style='color:#2F92EE;'>#疗效分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70400, encryptionId=e9bae04003f, topicName=疗效分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219323401160, createdName=rebeccajiejie, createdTime=Sun May 27 10:26:00 CST 2018, time=2018-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687090, encodeId=45cb168e0901b, content=<a href='/topic/show?id=b038851865c' target=_blank style='color:#2F92EE;'>#脓毒性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85186, encryptionId=b038851865c, topicName=脓毒性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd9828318255, createdName=1249857fm41暂无昵称, createdTime=Mon Jun 18 20:26:00 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290274, encodeId=6b2912902e44f, content=<a href='/topic/show?id=7d058518e56' target=_blank style='color:#2F92EE;'>#脓毒性休克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85187, encryptionId=7d058518e56, topicName=脓毒性休克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Wed Dec 06 01:26:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397405, encodeId=5b19139e405a6, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Wed Dec 06 01:26:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266939, encodeId=62a8266939aa, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Dec 05 08:45:14 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266722, encodeId=9565266e22e7, content=学习了.好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Dec 04 11:33:35 CST 2017, time=2017-12-04, status=1, ipAttribution=)]
    2017-12-05 1dd8c52fm63(暂无匿称)

    学习学习.继续关注

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1674612, encodeId=e4c316e4612d1, content=<a href='/topic/show?id=255c6e146aa' target=_blank style='color:#2F92EE;'>#烧伤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67146, encryptionId=255c6e146aa, topicName=烧伤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b15f27034396, createdName=俅侠, createdTime=Mon Jul 23 15:26:00 CST 2018, time=2018-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1647183, encodeId=9092164e18381, content=<a href='/topic/show?id=e9bae04003f' target=_blank style='color:#2F92EE;'>#疗效分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70400, encryptionId=e9bae04003f, topicName=疗效分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219323401160, createdName=rebeccajiejie, createdTime=Sun May 27 10:26:00 CST 2018, time=2018-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687090, encodeId=45cb168e0901b, content=<a href='/topic/show?id=b038851865c' target=_blank style='color:#2F92EE;'>#脓毒性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85186, encryptionId=b038851865c, topicName=脓毒性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd9828318255, createdName=1249857fm41暂无昵称, createdTime=Mon Jun 18 20:26:00 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290274, encodeId=6b2912902e44f, content=<a href='/topic/show?id=7d058518e56' target=_blank style='color:#2F92EE;'>#脓毒性休克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85187, encryptionId=7d058518e56, topicName=脓毒性休克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Wed Dec 06 01:26:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397405, encodeId=5b19139e405a6, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Wed Dec 06 01:26:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266939, encodeId=62a8266939aa, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Dec 05 08:45:14 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266722, encodeId=9565266e22e7, content=学习了.好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Dec 04 11:33:35 CST 2017, time=2017-12-04, status=1, ipAttribution=)]
    2017-12-04 1ddf0692m34(暂无匿称)

    学习了.好文章

    0

相关资讯

JAMA:一直以来建议的氢化可的松预防脓毒性休克,真的有效吗?

拯救脓毒症运动建议难治性感染性休克患者可使用辅助性氢化可的松治疗。但目前氢化可的松在严重脓毒症无休克患者中的疗效仍有争议。来自德国的研究人员开展了一项研究,该研究旨在确定在严重脓毒症患者中,氢化可的松治疗是否能够预防脓毒性休克的发展。该双盲,随机临床试验于2009年1月13日至2013年8月27日期间进行,随访期为180天,直至2014年2月23日。该试验在德国的34家大学和社区医院的中级或重症监

Chest:这3种药预防严重脓毒症和脓毒性休克患者器官衰竭效果好

2017年6月,发表在《Chest》的一项由美国科学家进行的回顾性前后研究,考察了氢化可的松、维生素C和硫胺素治疗严重脓毒症和脓毒性休克的有效性。

Liver Int:肥胖与脓毒性休克的肝硬化患者住院死亡率增高独立相关

体重指数(BMI)增加在病重肝硬化患者中很常见,与住院死亡率增加独立相关。

Crit Care Med:Olfactomedin-4 +中性粒细胞与脓毒性休克患者的死亡有什么关系?

脓毒症相关病理学中的异质性仍是一个重大的挑战。如果能解决这种异质性,将会让我们更了解相关病理学,同时改善患者的医疗护理。 Olfactomedin-4是中性粒细胞亚群标记物,可能会导致脓毒症的异质性。本研究的目的是,评估感染性休克儿童患者的olfactomedin-4表达情况,以及中性粒细胞的异质性特征。 本研究纳入了单中心、前瞻性队列,对单中心、前瞻性队列进行了二次分析。 研究

N Engl J Med:一项关于早期,目标定向治疗脓毒性休克的患者级Meta分析

一项关于早期、目标定向治疗脓毒性休克的患者级Meta分析表明,EGDT并没有导致比常规护理更好的结果,并且与各类特征的患者和医院较高的住院费用相关。

N Engl J Med:早期目标导向治疗脓毒性休克 贵但疗效没有更好

早期目标导向治疗(EGDT)能否减少脓毒性休克的死亡率,仍有争议。2017年6月,发表在《N Engl J Med》的一项个体患者数据的荟萃分析显示,EGDT不会比常规治疗产生更好的结局,并且在较宽的患者和医院特征范围内与较高住院费用相关。

Baidu
map
Baidu
map
Baidu
map